The design of ALLHAT may have biased the study's outcome in favor of the diuretic cohort

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981–2997

Davis BR et al. (2004) ALLHAT: setting the record straight. Ann Intern Med 141: 39–46

Houston MC (2004) ALLHAT debate: diuretics are not preferred, first-line initial therapy for hypertension. Arch Intern Med 164: 570–571

Morganti A (2005) Should a diuretic always be the first choice in patients with essential hypertension? The case for no. J Am Soc Nephrol 16 (Suppl 1): S70–S73

Messerli FH et al. (2004) Antihypertensive therapy and new onset diabetes. J Hypertens 22: 1845–1847

Wilmer WA et al. (2003) Management of glomerular proteinuria: a commentary. J Am Soc Nephrol 14: 3217–3232

Bloch MJ and Basile J (2006) Valsartan but not valsartan+ hydrochlorothiazide, moderately decreases C-reactive protein in patients with stage 2-hypertension: the Val-MARC trial. J Clin Hypertens (Greenwich) 8: 602–604

Hawkins RG and Houston MC (2005) Is population-wide diuretic use directly associated with the incidence of end-stage renal disease in the United States? A hypothesis. Am J Hypertens 18: 744–749

Smith NL et al. (2006) New-onset diabetes and risk of all-cause and cardiovascular mortality: the Cardiovascular Health Study. Diabetes Care 29: 2012–2017

The National Heart, Lung, and Blood Institute Working Group on Future Directions in Hypertension Treatment Trials (2005) Major clinical trials of hypertension: what should be done next? Hypertension 46: 1–6

Yusuf S et al. (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342: 145–153

PROGRESS Collaborative Group (2001) Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358: 1033–1041

Fox KM et al. (2003) Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362: 782–788